KRAS and lung adenocarcinoma: Moreover, an animal model with Kras activation combined with p53 deletion mice initiated lung adenocarcinoma development that demonstrated that NKX2-1 was only lost in malignant metastatic tumours, not in non-metastatic tumours [8].